104 related articles for article (PubMed ID: 34047794)
1. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
[TBL] [Abstract][Full Text] [Related]
2. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
3. Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials.
Fountzilas E; Vo HH; Mueller P; Kurzrock R; Tsimberidou AM
Eur J Cancer; 2023 Aug; 189():112927. PubMed ID: 37364526
[TBL] [Abstract][Full Text] [Related]
4. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
[TBL] [Abstract][Full Text] [Related]
5. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Váradi M; Horváth O; Módos O; Fazekas T; Grunewald CM; Niegisch G; Krafft U; Grünwald V; Hadaschik B; Olah C; Maráz A; Furka A; Szűcs M; Nyirády P; Szarvas T
Sci Rep; 2023 Oct; 13(1):17378. PubMed ID: 37833455
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis.
Yin G; Guo W; Huang Z; Chen X
Melanoma Res; 2022 Apr; 32(2):71-78. PubMed ID: 35254329
[TBL] [Abstract][Full Text] [Related]
8. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
[TBL] [Abstract][Full Text] [Related]
9. Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.
Watanabe S; Nonaka T; Maeda M; Yamada M; Sugii N; Hashimoto K; Takano S; Koyanagi T; Arakawa Y; Ishikawa E
Ther Innov Regul Sci; 2024 Jul; 58(4):655-662. PubMed ID: 38530629
[TBL] [Abstract][Full Text] [Related]
10. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study.
Funada S; Luo Y; Kataoka Y; Yoshioka T; Fujita Y; Yoshida S; Katsura M; Tada M; Nishioka N; Nakamura Y; Ueno K; Uozumi R; Furukawa TA
BMJ Evid Based Med; 2023 Nov; 28(6):372-382. PubMed ID: 37586872
[TBL] [Abstract][Full Text] [Related]
11. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis.
Shahnam A; Nindra U; Desai J; Hui R; Buyse M; Hopkins AM; Sorich MJ
J Natl Cancer Inst; 2023 Dec; 115(12):1475-1482. PubMed ID: 37540222
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Immune Checkpoint Inhibitors in Various Tumor Types Treated by Low, Per-Weight, and Conventional Doses at a Tertiary Care Center in Mumbai.
Patel A; Hande V; Mr K; Dange H; Das AK; Murugesan V; Bhatt T; Shankaran R
JCO Glob Oncol; 2024 Jan; 10():e2300312. PubMed ID: 38181308
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
Ranganathan S; Haslam A; Tuia J; Prasad V
J Cancer Policy; 2024 Mar; 39():100462. PubMed ID: 38061492
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
15. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
Redman MW; Goldman BH; LeBlanc M; Schott A; Baker LH
Clin Cancer Res; 2013 May; 19(10):2646-56. PubMed ID: 23669424
[TBL] [Abstract][Full Text] [Related]
16. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
Oxnard GR; Wilcox KH; Gonen M; Polotsky M; Hirsch BR; Schwartz LH
JAMA Oncol; 2016 Jun; 2(6):772-9. PubMed ID: 26914340
[TBL] [Abstract][Full Text] [Related]
17. Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.
Huang B; Tian L
Pharm Stat; 2022 Sep; 21(5):865-878. PubMed ID: 35191170
[TBL] [Abstract][Full Text] [Related]
18. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
19. PubPredict: Prediction of progression and survival in oncology leveraging publications and early efficacy data.
Zhang J; Guo Y; Zhou J; Rasmussen HE
Pharm Stat; 2023; 22(5):963-973. PubMed ID: 37439295
[TBL] [Abstract][Full Text] [Related]
20. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls.
Wright K; Mittal A; Gyawali B
Curr Opin Oncol; 2023 Nov; 35(6):513-521. PubMed ID: 37621175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
